The following is a review of a satellite symposium held at the EHRS Meeting in June 2006. U.B.P. reminded the audience that unwanted facial hair (UFH) is an important issue; over 40% of the women in the general population have some degree of UFH, and its psychological and psychosocial impact should not be underestimated. The treatment of UFH involves many different disciplines, and the symposium offered the latest thinking in different aspects of the disorder. S.L. outlined the current concepts surrounding polycystic ovarian syndrome, and U.G. addressed the psychological aspects of UFH. J.S. described the current treatment options for UFH, followed by U.B.P.’s evidence-based therapy review. Finally, R.H. reviewed the latest trial results with Trichoscan, a method being investigated for assessing UFH removal.

The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group: Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41–47.
Polson DW, Adams J, Wadsworth J, et al: Polycystic ovaries – A common finding in normal women.Lancet 1988;i:870–872.
Clayton RN, Ogden V, Hodgkinson J, et al: How common are polycystic ovaries in normal women and what is their significance for the fertility of the population? Clin Endocrinol (Oxf) 1992;37:127–134.
Michelmore KF, Balen AH, Dunger DB, et al: Polycystic ovaries and associated clinical and biochemical features in young women. Clin Endocrinol (Oxf) 1999;51:779–786.
Sharma A, Atiomo W: Recent developments in polycystic ovary syndrome. Curr Obstet Gynaecol 2003;13:281–286.
Franks S, Gharani N, Waterworth D, et al: The genetic basis of polycystic ovary syndrome. Hum Reprod 1997;12:2641–2648.
Franks S: Assessment and management of anovulatory infertility in polycystic ovary syndrome. Endocrinol Metab Clin North Am 2003;32:639–651.
Taylor AE, McCourt B, Martin KA, et al: Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82:2248–2256.
Laven JS, Imani B, Eijkemans MJ, et al: New approach to polycystic ovary syndrome and other forms of anovulatory infertility. Obstet Gynecol Surv 2002;57:755–767.
Slayden SM, Moran C, Sams WM Jr, et al: Hyperandrogenemia in patients presenting with acne. Fertil Steril 2001;75:889–892.
Wild S, Pierpoint T, Jacobs H, et al: Long-term consequences of polycystic ovary syndrome: results of a 31-year follow-up study. Hum Fertil (Camb) 2000;3:101–105.
Dahlgren E, Janson PO, Johansson S, et al: Polycystic ovary syndrome and risk for myocardial infarction: evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand 1992;71:599–604.
Wild RA: Polycystic ovary syndrome: a risk for coronary artery disease? Am J Obstet Gynecol 2002;186:35–43.
Hardiman P, Pillay OC, Atiomo W: Polycystic ovary syndrome and endometrial carcinoma. Lancet 2003;361:1810–1812. Erratum in Lancet 2003;362:1082.
Meyer AE, von Zerssen D: About methods for an initial psychosomatic investigation of clinical syndromes (exemplified by a research on the so-called idiopathic hirsutism). Fortschr Psychosom Med 1960;1:70–77.
Rabinowitz S, Cohen R, Le Roith D: Anxiety and hirsutism. Psychol Rep 1983;53:827–830.
Keegan A, Liao LM, Boyle M: Hirsutism: a psychological analysis. J Health Psychol 2003;8:327–345.
Kitzinger C, Willmott J: The thief of womanhood: women’s experience of polycystic ovarian syndrome. Soc Sci Med 2002;54:349–361.
Sonino N, Fava GA, Mani E, et al: Quality of life of hirsute women. Postgrad Med J 1993;69:186–189.
Housman TS, Derrow AE, Sniveley BM, et al: Women with excessive facial hair: a statistical evaluation and review of impact on quality of life. Cosmet Dermatol 2004;17:157–165.
Fava GA, Grandi S, Savron G, et al: Psychosomatic assessment of hirsute women. Psychother Psychosom 1989;51:96–100.
Barth JH, Catalan J, Cherry CA, et al: Psychological morbidity in women referred for treatment of hirsutism. J Psychosom Res 1993;37:615–619.
Strauss B, Appelt H: Psychological influences on the assessment of bodily symptoms in hirsutism. Psychother Med Psychol 1984;34:179–185.
Moreno-Arias CA, et al: Side-effects after IPL photodepilation. Dermatol Surg 2002;28:1131–1134.
Hirsch RJ, et al: Hair growth induced by laser hair removal (abstract). Lasers Surg Med 2003;32:63.
Marayiannis KB, Vlachos SP, Konoes PP: Efficacy of long- and short-pulse alexandrite lasers compared with an intense pulsed light source for epilation: a study on 532 sites in 389 patients. J Cosmet Laser Ther 2003;5:140–145.
Vlachos SP, Konoes PP, et al: Development of terminal hair following skin lesion treatments with IPL. Aesthet Plast Surg 2002;26:303–307.
Alajlan A, Shapiro J, Rivers JK, et al: Paradoxical hypertrichosis after laser epilation. J Am Acad Dermatol 2005;53:85–88.
Azziz R, Sanchez LA, Knochenhauer ES, Moran C, et al: Androgen excess in women: experience with over 1,000 consecutive patients. J Clin Endocrinol Metab 2004;89:453–462.
Richards RN, McKenzie MA, Meharg GE: Electroepilation (electrolysis) in hirsutism: 35,000 h’ experience on the face and neck. J Am Acad Dermatol 1986;15:693–697.
Hayashi S, Miyamoto I, Takeda K: Measurement of human hair growth by optical microscopy and image analysis. Br J Dermatol 1991;125:123–129.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.